88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease SUZHOU, China and MÖLNDAL, Sweden , May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of ... 2026-05-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery SHANGHAI , May 28, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated ... 2026-05-28T Biotechnology Computer/Electronics Health Care/Hospital Medical/Pharmaceuticals
Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer SHANGHAI and HONG KONG , May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ... 2026-05-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test SINGAPORE , May 28, 2026 /PRNewswire/ -- Gene Solutions , a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the ... 2026-05-28T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
HEALEY ALS Platform Trial Regimen I expands to 240 participants Highlights: ... 2026-05-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies SHANGHAI , May 27, 2026 /PRNewswire/ -- SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the ... 2026-05-27T Biotechnology Health Care/Hospital Publishing/Information Service
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery SHANGHAI , May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, " Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated ... 2026-05-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery SHANGHAI , May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated ... 2026-05-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV - Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone ... 2026-05-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer SHANGHAI , May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that ... 2026-05-27T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved